NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
This grant funds milestone-driven preclinical research to develop and advance new therapies for visual system diseases, supporting projects from early-stage lab findings through FDA IND/IDE submission readiness.
Funder: National Institutes of Health
Due Dates: November 16, 2029 (application closing date)
Funding Amounts: R61 up to 2 years; R33 up to 4 years; combined duration up to 5 years
Summary: Supports development of therapeutics for diseases and disorders of the visual system.
Key Information: Clinical trials are not allowed; every project begins with an R61 phase.
Description
The National Eye Institute’s Translational Research Program supports the rapid translation of laboratory findings into therapeutics clinicians can use to treat diseases or disorders of the visual system. It funds product development for biological, pharmaceutical, medical device, and combination therapies.
The program uses a two-phase, milestone-driven R61/R33 award. R61 supports research with significant preliminary data that has not yet reached clinical translation. R33 supports a single therapeutic candidate in the final stages of preclinical development, with potential for near-term clinical development. Its work focuses on IND/IDE-enabling studies, an FDA filing, and the design of future clinical trials.
